Vitae Pharmaceuticals (VTAE) Announces BI187004/VTP-34072 Phase 2 Missed Primary Efficacy Endpoint
- Stocks sink, oil jumps after Israeli attack on Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil surges as reports of Israeli strike on Iran roil markets
- Reports of Israeli attack on Iran spark rush to yen, Swiss franc
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Vitae Pharmaceuticals Announces Top-Line Results From Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics
June 29, 2015 6:32 AM EDTFORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11-hydroxysteroid dehydrogenase type 1 (11 HSD1) inhibitor that was discovered by Vitae and is currently being developed by Boehringer Ingelheim GmbH (Boehringer Ingelheim), a leader in diabetes treatments and cardiometabolic research and development.
Safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BI187004/VTP-34072 as monotherapy or... More
Vitae Pharmaceuticals Announces Top-Line Results From Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics
June 29, 2015 6:32 AM EDTFORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11-hydroxysteroid dehydrogenase type 1 (11 HSD1) inhibitor that was discovered by Vitae and is currently being developed by Boehringer Ingelheim GmbH (Boehringer Ingelheim), a leader in diabetes treatments and cardiometabolic research and development.
Safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BI187004/VTP-34072 as monotherapy or... More